AmgenNow直接面向消费者计划 - 安进公司推出名为AmgenNow的直接面向消费者计划，为首个参与产品降脂药Repatha提供大幅折扣[1] - Repatha在AmgenNow计划中的月定价为239美元，较美国标价有近60%的折扣[1][8] - 该直接面向患者的价格在七国集团发达经济体中为最低[2] Repatha产品表现与市场拓展 - Repatha第二季度销售额达6.96亿美元，同比增长31%，主要受美国市场可及性改善推动[4] - 公司预期Repatha到2030年将发展成为价值数十亿美元的产品系列[4] - 安进与药品储蓄平台GoodRx合作，在全美7万家药房以239美元的相同价格提供Repatha[3][8] 行业背景与政治压力 - 计划推出源于政治压力，要求制药公司将国内药价与其他发达国家看齐[3] - AmgenNow预计将通过预计明年上线的新联邦采购平台TrumpRx.gov进行访问[3] - 行业出现转向与政府加强合作的更广泛转变，安进和辉瑞的进展被视为可能缓解监管和定价压力的转折点[12] 公司国内投资与战略调整 - 安进上月宣布投资6.5亿美元以扩大其在美国的制造网络[10] - 近期一系列国内投资包括加州6亿美元的科学创新中心、俄亥俄州9亿美元的制造扩张以及北卡罗来纳州10亿美元的设施[10] - 辉瑞与政府达成里程碑协议，同意将其上市药品价格与其他发达国家匹配，并换取三年原料药进口关税豁免，同时计划未来几年额外投资700亿美元加强国内研发和生产[11]

公司行动 - 安进公司在美国直接向消费者推出降胆固醇药物Repatha [2] - Repatha以降低后的现金价格销售 [2] 行业背景 - 制药公司正面临政治压力 [2] - 此次行动是制药行业对政治压力的广泛回应之一 [2]

The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha. ...

Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to U.S. political pressur... ...

"Amgen is committed to finding new ways to help patients benefit from our medicines," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. "Repatha has already helped more than 5 million patients, and the AmgenNow program will make it easier for uninsured patients or those who choose to pay out-of-pocket to access treatment. This will allow even more Americans at increased risk of major adverse cardiovascular events to benefit from this effective medicine." Beginning today ...

For those with a sufficiently long investment horizon, the stock looks attractive.Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (AMGN 0.17%) started the year strong, but has not maintained that momentum. Over the past six months, Amgen's shares have declined by 9%. The drugmaker is facing some issues, including upcoming patent cliffs.Even so, there remain strong reasons to invest in Amgen and ho ...

股价表现 - 公司当前股价为29982美元 当日上涨082% [1] - 公司股价过去一个月上涨571% 但过去一年下跌555% [1] 估值水平分析 - 公司市盈率为2432 低于生物技术行业平均市盈率3041 [6] - 较低市盈率可能意味着股票被低估 也可能预示其表现将逊于同业 [6] 估值指标解读 - 市盈率是衡量当前股价与每股收益之比的指标 被长期投资者用于分析公司当前表现 [5] - 较高市盈率通常反映投资者对公司未来业绩有更高期望 或意味着股票可能被高估 [5]

Let's get stop trading with Jim. >> One thing that some people may have missed came out yesterday was that Amgen had a landmark study that went very well for Rapatha uh lowering cholesterol and therefore do you know helping people's hearts even if you don't have cholesterol. Now I'm on this uh Rapatha because my doctor is basically part of this trial and just said look there's no level of cholesterol that's good.uh they're also they're not doing a study on this but people feel that reduces plaque but I thin ...

核心观点 - 安进公司宣布其药物Repatha在VESALIUS-CV三期临床试验中达到双重主要终点，证明在标准疗法基础上加用Repatha可显著降低无心肌梗死或卒中病史的高风险患者的主要不良心血管事件风险 [1] - Repatha成为首个且唯一被证明在无心血管事件病史患者中作为一级预防和二级预防均能显著降低心血管事件的PCSK9抑制剂 [1][4] - 试验结果标志着心血管疾病治疗的重要里程碑，有望将Repatha的适用人群扩展至数千万更早期的患者 [4] 临床试验结果 - VESALIUS-CV试验入组了超过12,000名高风险患者，中位随访时间约4.5年 [1][9] - 约85%的患者在接受高强度或中等强度LDL-C降低疗法 [1] - 试验达到双重主要终点，包括冠心病死亡、心肌梗死或缺血性卒中复合终点时间，以及冠心病死亡、心肌梗死、缺血性卒中或缺血驱动的动脉血运重建复合终点时间 [3] - 结果显示主要终点具有统计学和临床显著性，未观察到新的安全性信号 [3] 药物背景与市场地位 - Repatha于2015年首次获批，已在全球被超过670万患者使用 [6] - 该药物是研究最广泛的PCSK9抑制剂，拥有超过57,000名患者参与的51项临床试验数据，安全性和临床效益已研究15年 [12] - 今年美国FDA扩大了Repatha的批准用途，包括因LDL-C控制不佳而具有主要不良心血管事件风险的成人 [6] - Repatha已在74个国家获批，包括美国、日本、加拿大和所有28个欧盟成员国 [12] 疾病背景与未满足需求 - 心血管疾病是全球主要死亡原因，美国每40秒就发生一次心肌梗死或卒中，其中75%为首次事件 [5] - 高LDL-C是心肌梗死和卒中最可改变的风险因素之一，但近期研究显示超过80%无心血管事件病史的高风险患者在一年随访后未达到LDL-C低于70 mg/dL的推荐水平 [5] 公司研发战略 - 安进公司在心血管疾病领域拥有数十年领导地位，正通过LDL-C管理推进针对心血管疾病常见驱动因素的创新研究性治疗 [10] - 公司通过科学创新与战略合作相结合，推动早期检测、更好护理和更广泛可及性，体现对心血管护理科学和系统的持续承诺 [10]

These stocks have been raising their payouts much faster than most dividend payers.There are a million and one ways to put your money to work on Wall Street. It might surprise you to learn that investing in dividend growth stocks isn't just one of the easiest; it's also one of the most effective.Between 1973 and 2024, shares of companies in the benchmark S&P 500 index that grew or initiated a dividend produced a 10.24% average annual return. Stocks that didn't offer a dividend produced a measly 4.31% averag ...